FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

• click to rate

  Posted by Two Blokes Jul 25 - Filed in Stock - 1 view
  
  SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.